Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%. The most common factors predicting survival are presence of metastases, histological response to preoperative chemotherapy and complete surgical resection. Four of the active drugs in osteosarcoma include cisplatin, doxorubicin, high-dose methotrexate and ifosfamide and this combination (MAPI), given preoperatively and postoperatively, is widely used for the treatment of osteosarcoma in China. Apatinib also has activity in advanced setting and when incorporated into the treatment of patients with metastatic disease seemed to improve progression-free survival. Combination of apatinib and camrelizumab resulted in durable therapuetic effect in selected cases. Though EURAMOUS-1 suggested that changing chemotherapy postoperatively on the basis of histological response did not improve outcomes. The exploratory study with radomised design to compare combination of chemotherapy with target drug or combination of chemotherapy with anti-PD-1 antibody versus standard chemotherapy has not been tried yet. Thus we aim to investigate the efficacy and toxicity of these combiantions versus standard chemotherapy in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

NCT04824352

Effect of Drug Toxicity, Drug

SUSPENDED PHASE2

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

NCT00134030

Localized Osteosarcoma Metastatic Osteosarcoma

COMPLETED PHASE3

Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity

NCT02273583

High Grade Osteosarcoma

UNKNOWN PHASE2

Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma

NCT00645632

Sarcoma

COMPLETED NA

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer

NCT00011921

Lung Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteosarcoma Survival Chemotherapy Effect Toxicity, Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

API+apatinib

AP = Doxorubicin (Adriamycin) 20 mg/m2/day \* 2 day (total/cycle 40 mg/m²)

\+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);

I = Ifosfamide 2000 mg/m2/day \*5 day (total/cycle 10000 mg/m²);

apatinib = 500 mg QD;

Group Type EXPERIMENTAL

MAPI chemotherapy

Intervention Type DRUG

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Apatinib Mesylate

Intervention Type DRUG

anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily

MAPI+camrelizumab

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);

M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;

I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²);

camralizumab = 200mg ivgtt. Q2W;

Group Type EXPERIMENTAL

MAPI chemotherapy

Intervention Type DRUG

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Camrelizumab

Intervention Type DRUG

anti-PD-1 antibody 200mg ivgtt. Q2W

MAPI

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);

M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;

I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²);

Group Type ACTIVE_COMPARATOR

MAPI chemotherapy

Intervention Type DRUG

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MAPI chemotherapy

AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)

\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)

Intervention Type DRUG

Apatinib Mesylate

anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily

Intervention Type DRUG

Camrelizumab

anti-PD-1 antibody 200mg ivgtt. Q2W

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed high-grade osteosarcoma, including second malignancies
* Tumor (primary, metastatic, or both) resectable OR is expected to become resectable after neoadjuvant induction chemotherapy
* Suitable for neoadjuvant chemotherapy and adjuvant chemotherapy
* Performance status - Lansky 50-100% (for patients under 16 years of age); Performance status - WHO or ECOG 0-2 with a life expectancy \>3 months
* normal cardiac function (shortening fraction \>28%), normal hearing, normal bone marrow as shown by an absolute neutrophil count of at least 1·5 × 10⁹ cells per L (or a white blood cell count of at least 3 × 10⁹ cells per L if neutrophil count is not available), and a platelet count of at least 100 000 platelets per μL
* Patients were also required to have a serum bilirubin concentration of at most less than 1·5 times the upper limit of normal and a normal creatinine concentration for their age as per protocol
* Women of child-bearing potential had to take adequate contraceptive measures and have a negative pregnancy test within 7 days of study entry.

Exclusion Criteria

* patients who have recieved anti-angiogenic TKIs or anti-PD-1/PD-L1 antibodies
* allergy to chemotherapy or apatinib or camrelizumab
* other severe illness (eg, psychosis or previous history of cardiovascular disease)
* symptomatic or known CNS metastases
* previous or concurrent second primary malignant tumours
* had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++, and so on
* had other infections or wounds
* pregnant or breastfeeding.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No